BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36065524)

  • 21. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
    Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.
    Ksienski D; Truong PT; Wai ES; Croteau NS; Chan A; Patterson T; Clarkson M; Hackett S; Irons S; Lesperance M
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e561-e569. PubMed ID: 34226113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
    Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
    Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma.
    Takahashi A; Namikawa K; Ogata D; Nakano E; Jinnai S; Nakama K; Tsutsui K; Muto Y; Mizuta H; Yamazaki N
    J Dermatol; 2020 Nov; 47(11):1267-1275. PubMed ID: 32725685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients.
    Salaün H; de Koning L; Saint-Ghislain M; Servois V; Ramtohul T; Garcia A; Matet A; Cassoux N; Mariani P; Piperno-Neumann S; Rodrigues M
    Oncoimmunology; 2022; 11(1):2116845. PubMed ID: 36092639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
    Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T
    Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863
    [No Abstract]   [Full Text] [Related]  

  • 28. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
    Postow MA; Chesney J; Pavlick AC; Robert C; Grossmann K; McDermott D; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor D; Salama AK; Taylor M; Ott PA; Rollin LM; Horak C; Gagnier P; Wolchok JD; Hodi FS
    N Engl J Med; 2015 May; 372(21):2006-17. PubMed ID: 25891304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
    Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
    Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
    Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
    Dearden H; Au L; Wang DY; Zimmer L; Eroglu Z; Smith JL; Cuvietto M; Khoo C; Atkinson V; Lo S; Long GV; Sandhu S; Ascierto PA; Carlino MS; Johnson DB; Larkin J; Menzies AM
    Eur J Cancer; 2021 Aug; 153():168-178. PubMed ID: 34182268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
    Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
    BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Namba Y; Yamazaki N
    J Dermatol; 2020 Nov; 47(11):1257-1266. PubMed ID: 32812243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
    Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
    J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
    McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
    Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.